Global Anemia in Chronic Kidney Disease Market and Forecast Analysis 2018-2035: The Launch of Novel HIF Inhibitor Roxadustat will Offset Biosimilar Erosion of Epogen to Drive Market Growth

News provided by

Research and Markets

15 Feb, 2018, 13:15 GMT

DUBLIN, Feb. 15, 2018 /PRNewswire/ --

The "Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035" report has been added to ResearchAndMarkets.com's offering.

Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.


Market Snapshot

  • The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.
  • Physicians expect to switch a significant portion of patients on stable erythropoiesis-stimulating agent (ESA) therapy to oral ESAs within three years of their launch.
  • Between 2015 and 2035, the number of prevalent cases of anemia in chronic kidney disease (CKD) is forecasted to increase from 11.3 million to 14.9 million. This is due to a forecasted increase in the number of prevalent CKD cases, which is driven by population growth and aging, although increasing diabetes prevalence will also play a major role in shaping the future prevalence of anemia in CKD.
  • Use of erythropoiesis-stimulating agents, the standard of care for anemia in CKD, may decline due to cost and safety concerns.
  • Pipeline therapies plan to capture market share by reducing costs and safety concerns associated with treatment.

Key Topics Covered:

Forecast: Anemia In Chronic Kidney Disease

  • Executive Summary
  • Recent Forecast Updates
  • Market Dynamics
  • Forecast And Future Trends
  • Market Definition And Methodology
  • Primary Research Methodology
  • Product Profile: Aranesp
  • Product Profile: Auryxia
  • Product Profile: Dexferrum
  • Product Profile: Epogen
  • Product Profile (Late Stage): Feraccru
  • Product Profile: Feraheme
  • Product Profile: Injectafer
  • Product Profile: Mircera
  • Product Profile: Neorecormon
  • Product Profile: Venofer
  • Product Profile (Late Stage): Roxadustat

Treatment: Anemia In Chronic Kidney Disease

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Country Treatment Trees
  • Current Treatment Options
  • Prescribing Trends
  • Unmet Needs In Anemia In Chronic Kidney Disease
  • Future Treatment

Epidemiology: Anemia In Chronic Kidney Disease

  • Executive Summary
  • Sources And Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths And Limitations

Marketed Drugs: Anemia In Chronic Kidney Disease

  • Executive Summary
  • Product Overview
  • Product Profile: Aranesp
  • Product Profile: Auryxia
  • Product Profile: Dexferrum
  • Product Profile: Epogen
  • Product Profile: Feraheme
  • Product Profile: Injectafer
  • Product Profile: Mircera
  • Product Profile: Neorecormon
  • Product Profile: Venofer

Pipeline: Anemia In Chronic Kidney Disease

  • Executive Summary
  • Clinical Pipeline Overview
  • Product Profile (Late Stage): Feraccru
  • Product Profile (Late Stage): Roxadustat


For more information about this report visit https://www.researchandmarkets.com/research/tphdjk/global_anemia_in?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets